Iovance Biotherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IOVA research report →
Companywww.iovance.com
Iovance Biotherapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
- CEO
- Frederick G. Vogt
- IPO
- 2010
- Employees
- 838
- HQ
- San Carlos, CA, US
Price Chart
Valuation
- Market Cap
- $1.27B
- P/E
- -4.19
- P/S
- 4.43
- P/B
- 2.05
- EV/EBITDA
- -3.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 114.51%
- Op Margin
- -127.16%
- Net Margin
- -123.90%
- ROE
- -50.17%
- ROIC
- -45.33%
Growth & Income
- Revenue
- $263.50M · 60.60%
- Net Income
- $-390,978,000 · -5.05%
- EPS
- $-1.09 · 14.84%
- Op Income
- $-403,356,000
- FCF YoY
- 7.64%
Performance & Tape
- 52W High
- $5.63
- 52W Low
- $1.66
- 50D MA
- $3.69
- 200D MA
- $2.81
- Beta
- 0.69
- Avg Volume
- 17.50M
Get TickerSpark's AI analysis on IOVA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Kirby Daniel Gordon | other | 10,000 |
| May 11, 26 | Kirby Daniel Gordon | other | 2,435 |
| May 11, 26 | Kirby Daniel Gordon | other | 10,000 |
| Mar 9, 26 | Roche Corleen M. | other | 132,200 |
| Mar 9, 26 | Vogt Frederick G | other | 235,000 |
| Mar 9, 26 | Puri Raj K. | other | 117,500 |
| Mar 9, 26 | GRAF FINCKENSTEIN FRIEDRICH | other | 58,750 |
| Mar 9, 26 | Kirby Daniel Gordon | other | 132,200 |
| Mar 9, 26 | BILINSKY IGOR | other | 117,500 |
| Mar 5, 26 | Vogt Frederick G | other | 62,493 |
Our IOVA Coverage
We haven't published any research on IOVA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IOVA Report →